2023-06-29 0
The Phase II clinical study achieved the primary clinical endpoint and safety Excellent, adverse reactions in the eyes and injection site are lower than similar products.
The excellent results of the MG-K10-AD-2 clinical study are expected to bring new hope to many patients with moderate to severe atopic dermatitis.
All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com